PALISADE BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum
PALISADE BIO, INC. (PALI) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum of 55.50% for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-15.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum · last filed 2013-03-15
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for fiscal 2012 was 55.50%, a 17.04% decline from fiscal 2011.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for fiscal 2011 was 66.90%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 12 month |
|---|---|---|---|
| 2012-12-31 | 55.50% 10-K · filed 2013-03-15 | ||
| 2012-09-30 | 55.50% 10-Q · filed 2012-11-09 | ||
| 2012-06-30 | 55.50% 10-Q · filed 2012-08-09 | ||
| 2011-12-31 | 66.90% 10-K · filed 2013-03-15 | ||
| 2011-09-30 | 59.90% 10-Q · filed 2012-11-09 | ||
| 2011-06-30 | 72.60% 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |